Research progress on glucose-regulated protein 78 in drug resistance and targeted therapy for cancer

doi:10.19401/j.cnki.1007-3639.2018.02.013

China Oncology ›› 2018, Vol. 28 ›› Issue (2): 156-160.doi: 10.19401/j.cnki.1007-3639.2018.02.013

Research progress on glucose-regulated protein 78 in drug resistance and targeted therapy for cancer

ZHENG Yizi, SHAO Zhimin

Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Online:2018-02-28 Published:2018-03-08
Contact: SHAO Zhimin E-mail: zhi_ming_shao@163. com

Abstract

Abstract: Glucose-regulated protein 78 (GRP78) plays an important role in the development of drug resistance in cancer, and GRP78 targeted therapy has become a hotspot of cancer research. In this article, we briefly introduce GRP78, review the research progress on the roles of GRP78 in drug resistance to cancer therapies, including chemotherapy, endocrine therapy and targeted therapy, and the mechanisms of resistance. The progress on GRP78 targeted therapy for cancer is also summarized.

Key words: Glucose-regulated protein 78, Cancer, Drug resistance, Targeted therapy

ZHENG Yizi, SHAO Zhimin. Research progress on glucose-regulated protein 78 in drug resistance and targeted therapy for cancer[J]. China Oncology, 2018, 28(2): 156-160.

[1]	ZHU Xinzhe, LI Hao, XU Huaxiang, LUO Guopei, YU Xianjun. Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021 [J]. China Oncology, 2022, 32(1): 1-12.
[2]	JIA Zhenzhen, HE Shuang, LI Yangyang, WEN Feifei, XU Xiaoyang, GUO Ningjie, WU Shuhua. Correlations between expressions of DPD, LC3 and P62 in colorectal cancer and their clinical significance [J]. China Oncology, 2022, 32(1): 24-33.
[3]	ZHANG Chi, CHEN Jiahui, LIN Jinyi, WANG Yan, ZHANG Sijia, ZHU Wei, CHENG Leilei. Validation of a scale for evaluating the cardiovascular risk after breast cancer therapy: the clinical scale for breast cancer treatment related cardiovascular toxicity [J]. China Oncology, 2022, 32(1): 54-60.
[4]	JIN Yizi, LIN Mingxi, ZHANG Jian. Targeting DNA damage response deficiency in the treatment of breast cancer [J]. China Oncology, 2022, 32(1): 61-67.
[5]	XU Wenhao, TIAN Xi, Aihetaimujiang·Anwaier , QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei. A systematic review of current advancements of artificial intelligence in genitourinary cancers [J]. China Oncology, 2022, 32(1): 68-74.
[6]	Expert group of expert consensus on neoadjuvant treatment of breast cancer in China (2021 edition) . Expert consensus on neoadjuvant treatment of breast cancer in China (2021 edition) [J]. China Oncology, 2022, 32(1): 80-89.
[7]	WANG Zezhou , ZHANG Yang , MO Miao , YUAN Jing , ZHOU Changming , SHEN Jie , FENG Xiaoshuang , WU Haoxuan , LI Hang , YE Ting , HU Hong , CHEN Haiquan , ZHENG Ying . Distribution of metastatic sites and survival analysis of patients with non-metastatic lung cancer at initial diagnosis based on hospital registration [J]. China Oncology, 2021, 31(9): 775-782.
[8]	ZHANG Xiaoyan , LI Qingxiang , LIU Yong , LI Hang , QIU Lijuan , FENG Xinran , TAN Liming . A study on the correlation between HMGB1 and clinical characteristics and immune function in patients with breast cancer [J]. China Oncology, 2021, 31(9): 783-788.
[9]	CAO Ailing, CAO Zhe, ZHOU Jian. Effects of docetaxel combined with thymosin α1 on number of Treg in immune microenvironment of rats with breast cancer and its mechanism [J]. China Oncology, 2021, 31(9): 799-806.
[10]	YAO Jia , LI Guanqiao , YANG Shiping , SU Huiluan . Effect of hsa-miR-98-5p/DKK3 signal axis on biological behavior of breast cancer cells [J]. China Oncology, 2021, 31(9): 807-816.
[11]	LU Li, LU Renquan, SUN Jiajun, LU Ning, GUO Lin. The application of serum N-MID in auxiliary diagnosis and therapeutic effect monitoring of bone metastasis in patients with primary lung cancer [J]. China Oncology, 2021, 31(9): 838-844.
[12]	MA Yifei , LIANG Xinjun , WEI Shaozhong . Prognostic value of inflammatory and immune markers in resectable colorectal cancer [J]. China Oncology, 2021, 31(9): 845-851.
[13]	Tumor Support and Rehabilitation Therapy Group, the Oncology Committee of Chinese Medical Association. Clinical practice guidelines for cancer-related fatigue in China (2021 edition) [J]. China Oncology, 2021, 31(9): 852-872.
[14]	CONG Binbin, WANG Yongsheng. Treatment landscape and challenges of managing the hormone receptor-positive early breast cancer [J]. China Oncology, 2021, 31(8): 689-696.
[15]	FANG Yanhui , MA Caijuan , ZHANG Chunli , ZHAI Jiawei , ZHU Qiaoying , LIU Yin , ZHAO Xiwa . miR-496 inhibits proliferation, migration and invasion of HeLa cell in cervical cancer via SFMBT1 [J]. China Oncology, 2021, 31(8): 697-703.

Research progress on glucose-regulated protein 78 in drug resistance and targeted therapy for cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments